These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prediagnostic plasma enterolactone levels and mortality among women with breast cancer.
    Author: Olsen A, Christensen J, Knudsen KE, Johnsen NF, Overvad K, Tjønneland A.
    Journal: Breast Cancer Res Treat; 2011 Aug; 128(3):883-9. PubMed ID: 21340481.
    Abstract:
    Experimental and epidemiological studies have suggested that the phytoestrogen enterolactone is associated to biological mechanisms that may have positive effects on breast cancer development. In a recent study based on American breast cancer patients, high intakes of lignans, the precursor of enterolactone, was found related to lower mortality. The aim of this study was, for the first time, to evaluate if prediagnostic plasma levels of enterolactone were associated to mortality in women diagnosed with breast cancer. Among 24,697 postmenopausal women included into a Danish cohort between 1993 and 1997, 424 developed breast cancer before December 31, 2000. Enterolactone levels were measured in baseline blood samples and related to mortality by Cox proportional hazard models. During a median of 10 years after breast cancer diagnosis, 111 women died (80 from breast cancer). When comparing women with enterolactone levels above the median (>20.5 nmol/l) to those with lower levels, decreased hazard rates (HR) were seen for both all-cause mortality (HR: 0.47; 95% confidence interval: 0.32-0.68) and breast cancer mortality (HR: 0.56; 95% confidence interval: 0.36-0.87). Higher prediagnostic plasma levels of enterolactone were found related to lower mortality among breast cancer patients.
    [Abstract] [Full Text] [Related] [New Search]